Cycle Pharmaceuticals Launches Sajazir for HAE
The company has also launched a website for patients affected by hereditary angioedema, a rare genetic disorder.
Cycle Pharmaceuticals has launched Sajazir (icatibant) injection, a new treatment option for patients affected by hereditary angioedema (HAE). The therapy is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.
Hereditary angioedema is a rare genetic potentially life-threatening disorder that results in recurring attacks of edema in various parts of the body, including the abdomen, extremities (hands/feet), genitals, face, and throat. It affects about 1 in 50,000 people. Type I is the most common, accounting for 85% of cases.
The company has also launched a newly created website for patients, called Cycle Vita, which is a support hub for those with rare diseases (www.cyclevita.life).
John Reid
“Cycle Vita is an essential part of our core mission to better support patients with HAE and their families. We will appropriately guide patients through every stage of their journey by streamlining the enrollment and finance process and provide ongoing treatment support in addition to the expertise of the patient’s health care team.” John Reid, director of patient hub services, said in a statement.
Sajazir is supplied in a prefilled syringe. Patients may self-administer the therapy subcutaneously upon recognition of symptoms of a HAE attack after training under the guidance of a health care professional or a registered nurse from Cycle Vita.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More
